About Us

Have questions about Polaryx® Therapeutics or our innovative approach? Interested in partnering with us? Reach out. Let’s talk.

Who We Are


image description

Hahn-Jun Lee, M.Sc., Ph.D.

President / CEO

Dr. Lee is a serial entrepreneur who founded Polaryx Therapeutics, Inc to develop patient-friendly oral drugs for lysosomal storage disorders, such as Neuronal Ceroid Lipofuscinosis, Niemann Pick disease, Tay Sachs disease, and Krabbe disease which are devastating pediatric genetic disorders. He founded Epygenix Therapeutics, Inc. to develop precision medicines for rare and intractable genetic epilepsies, such as Dravet syndrome and Curyx Bio, Inc. to develop fist-in-class drugs for Parkinson’s Disease, Huntington’s Disease, and Glycine Encephalopathy. He also founded Focus Therapeutics, L.L.C. which plays a catalytic role in US and Asian Pacific biotechnology companies.

He has extensive experiences in R&D, deal making, business development, and consulting for top-notch health care venture capital firms and global pharma and biotech companies including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, and CDI. He has also consulted Korean biotechs, venture capital firms, and research institutes.

Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.

He obtained his B.S. in Life Science from Sogang University, Seoul, Korea. He obtained his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology from the University of Tokyo, Japan.

Scientific Advisory Board

image description

Dr. Kalipada Pahan, Ph.D

Chair of Scientific Advisory Board

Dr. Pahan is a Professor of Neurological Sciences, Biochemistry and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair in Neurology at the Rush University Medical Center in Chicago. He is also a Veterans Affairs Scientist at the Jesse Brown VA Medical Center. Currently, he is engaged in translational biomedical research involving Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, and Batten Dsease. He is the Editor-in-Chief of the Journal of Multiple Sclerosis, Senior Editor of the Journal of Neuroimmune Pharmacology, Editor of three other journals, and a chartered member of the Clinical Neuroimmunology and Brain Tumors study section at the NIH.

He has over 160 publications and is cited by Wikipedia. He received the outstanding teaching award in 2000, the “Chancellor’s Council Silver U Award” in 2004 and the "Reinhardt Research Scholar Award” in 2005 from the University of Nebraska Medical Center. Recently he also received VA merit awards from the US Department of Veterans Affairs and the Zenith award from the Alzheimer’s Association.

image description

Dr. Hynda Kleinman, Ph.D.

Hynda K. Kleinman received an MS and a Ph.D from Massachusetts Institute of Technology in 1971 and 1974, respectively. After a postdoctoral fellowship at Tufts University from 1973-1975, she directed a research lab at the NIH from 1975-2006. She has published over 430 papers and has 9 patents, 2 of which have been successfully commercialized. Matrigel is used worldwide for various in vitro/in vivo assays and was among the top 15 NIH patents bearing royalties for many years. The regenerative protein thymosin beta 4 is currently in phase 3 trials for ocular injuries. She has received numerous national/international awards for her scientific accomplishments, including the Hildegard Doerenkamp-Gerhardt Zbinden Award for developing “an in vitro assay for screening anti-cancer compounds which spares animals”. She received the Debio Peptide Award for identifying a peptide which inhibits cancer growth and metastases, the WISE (Women in Science and Engineering) Award for “being the most outstanding woman scientist in the federal government”, and the Senior Woman in Science Award from the American Society for Cell Biology for “her scientific achievement and strong commitment to the fostering of women in science.” She is currently a consultant to various biotech companies, including Bioqual Inc, Polaryx® Therapeutics, RegeneRx Biopharmaceuticals, Inc., and etc.

image description

David R. Luke, BScPhm., PharmD, FACA, FCCP

Dr. Luke received his BScPhm degree at the University of Toronto, PharmD degree at the Philadelphia College of Pharmacy and Sciences, and completed a 2-year fellowship in infectious diseases and nephrology at the University of Minnesota. His achievements include 12 NDA approvals in many different therapeutic areas, more than 2 dozen INDs, active participation in FDA meetings, 120+ peer-reviewed publications, 2 chapters, 100+ posters and presentations, and patent holder of initiatives involving HIV, fungal disease, and acute kidney injury. Outside of PhRMA, Dr. Luke has served as an advisory consultant with NASA/Johnson Space Center Steering Committee on the study of drugs in zero-gravity environment, officer of the Connecticut Medical Reserve Corps, and officer of various medical societies. Dr. Luke has held leadership positions at Pfizer Global Research and Development, Roche, Alexion, and Melinta Pharmaceuticals, and recently with Target Health Inc., as well as academic positions at the University of Minnesota, University of Texas MD Anderson Cancer Center, University of Houston College of Pharmacy, and Rutgers College of Pharmacy.

Medical Advisory Board

image description

Dr. Raymond Y. Wang, M.D.

Dr. Raymond Wang, M.D. is the Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s Hospital and a board certified clinical geneticist and biochemical genetics specialist. Dr. Wang is aware of the challenges faced by patients and families with rare diseases such as lysosomal storage disorders. He has committed the program to provide: treatment for the lysosomal disorders that have existing therapies; access to investigational treatment for patients with disorders that currently have no approved / effective therapy, and translational research vital to development of “next generation” treatments and cures for lysosomal storage disorder patients. He has participated in clinical trials for Type 2 Neuronal Ceroid Lipofuscinosis, Pompe Disease, Niemann-Pick C Disease, and Mucopolysaccharidoses. He also is the principal investigator for translational research involving gene therapy and gene editing for treatment of lysosomal storage disorders.

Dr. Wang graduated from Stanford University with Honors and Distinction in Biological Sciences. He earned his medical degree from the University of California, Los Angeles (UCLA), and completed his internship and residency in medical genetics and pediatrics at Cedars-Sinai Medical Center where he served as chief resident in his final year of training. Dr. Wang completed his fellowship in biochemical genetics at the UCLA Intercampus Medical Genetics Program. In 2006, Dr. Wang received the American College of Medical Genetics and Genzyme Fellowship in Biochemical Genetics Award and the Cedars-Sinai Medical Center’s Paul Rubenstein Prize for Excellence in Resident Research. Dr. Wang has been named an Orange County Clinical Biochemical Genetics Physician of Excellence in 2015, 2016, 2017, 2018, and 2019 and nominated for a 2018 Global Genes RARE Champion of Hope Award for his work with children with rare metabolic conditions.

Batten disease presents as seizures and / or vision failure followed by progressive motor dysfunction and cognitive decline.

Board of Directors

image description

Hahn-Jun Lee, M.Sc., Ph.D.

image description

Alex Yang, J.D.

Mr. Yang has over 20 years of experience in advising and executing fund formation, cross-border transactions and a diverse pool of investment experiences in multiple industry sectors.

He currently serves investment and risk committee member roles for various regional and country-focused private equity funds. Mr. Yang is formerly a managing partner at Kim & Chang and was a partner at Ernst & Young Hong Kong office leading their regional financial services practice, including banking and capital markets, asset management and insurance.

Mr. Yang formerly worked at Morgan Stanley Hong Kong Office in the capacity of its Asia Private Equity and In-house Counsel, focused on buy-outs and growth-capital investments, real estate, special situation and infrastructure transactions across Asia. He also worked at Coopers & Lybrand and Ernst & Young New York offices in their international tax and consulting divisions.

Mr. Yang graduated from New York University School of Law with both J.D. and L.L.M. degrees and Binghamton University with an Economics degree. He is a registered foreign attorney with the Hong Kong Law Society.


image description

Established in 2013, Mstone Partners makes principal investments and provides asset management and financial advisory services worldwide with a primary focus in the Asia-Pacific region. Our investment strategy focuses on two specific industry sectors: 1) healthcare & bio; and 2) real estate. With our experienced team of professionals and extensive network of industry experts, we assist small and medium enterprises in expanding their businesses overseas.

image description

Established in 1963, Youngpoong Pharma Co., Ltd has been regarded as one of major players in Korean pharmaceutical industry. The company is providing new and generic versions of pharmaceuticals to aid patients in the fields of infection, inflammation, cancer, diabetes, blood pressure, skin, digestive system, and urinary system. The company willcontinuously introduce valuable pharmaceuticals to the market to aid patients and improve human health.

image description

SV investment corp (SV) is one of the leading investment firms in S. Korea. SV has been regarded as a top cooperative-friendly company selected by 45 business partners and 11 LPs in S. Korea and abroad with successful investment accomplishments. SV invests in companies to create a value by providing right strategy and business guidance to support each stage of a company. Every year, SV was able to grow total AUM based on its excellent track record, and currently 12 VC funds and a PE fund are in operation to invest in promising biotech and IT companies.

We are seeking partners to help bring Polaryx's®
medications to children in need. Interested?

Click here to reach out.

Contact Now